drugset / Trial / NCT00189982
Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of children with hemophilia A. The study is open to pediatric patients in Canada who completed Baxter Study 060101.
Timeline
- Start
- 2004-12-17
- Primary completion
- 2006-11-10
- Completion
- 2006-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Antihemophilic Factor | Unknown | 25 iu/kg | — |
| Subject | Recombinant Antihemophilic Factor | Unknown | 50 iu/kg | — |